复星医药控股子公司就诊疗一体化核药项目SRT-007 于中国境内启动Ⅰ期临床试验

Core Viewpoint - Fosun Pharma (600196)(02196) has initiated Phase I clinical trials for its integrated nuclear medicine project SRT-007 in mainland China, targeting the diagnosis and treatment of PSMA-positive metastatic castration-resistant prostate cancer [1] Group 1 - The project SRT-007 is developed by Chengdu Xingrui Jingxuan Biotechnology Co., Ltd., a subsidiary of Fosun Pharma [1] - The clinical trial is specifically focused on patients with PSMA-positive metastatic castration-resistant prostate cancer [1]